For many patients, breast cancer causes more apprehension than any other potential risk with hormone therapy. Addressing the question of whether or not hormone therapy impacts breast cancer risk ends up being critical to whether patients initiate and continue hormone therapy.
In this audiocast, Daniel R. Mishell Jr, MD, and Andrew M. Kaunitz, MD discuss the evidence regarding the risk of gynecologic cancers with estrogen-only and combination hormone therapy. They review the results from a recent French cohort study that considered how the type of progestogen affects breast cancer risk, and offer recommendations for patient counseling about menopausal hormone therapy.
Click here to listen to audio discussion.
Click here to download accompanying slides.